Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities
Item Entry 1.01 into a Material Definitive Agreement. On June 23, 2026, Oncotelic Therapeutics, Inc. (the “Company” or “Our”) entered into a Securities Purchase Agreement (the “2026 Pacific Pier SPA ”), with Pacific Pier Capital II, LP (“ Pacific Pier ”), and the Company issued a convertible promissory note in the aggregate gross principal amount of $178,410 (the “ 2026 Pacific Pier Note ”).…
Filed Jun 29, 2026Accepted Jun 29, 2026, 5:15 PM EDTCIK 908259Accession 0001493152-26-031124
We are a clinical-stage biopharmaceutical company developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. After the acquisition of Mateon Therapeutics, Inc through a reverse merger in 2019, we realigned the company pipeline to focus on various cancers, including but not limited to rare pediatric cancers. The United States Food and Drug Administration (“FDA”) has granted us Rare Pediatric Designations (“RPD”) for pediatric Diffuse Intrinsic Pontine Glioma (“DIPG”) for OT-101, which was transferred to our joint venture as part of the joint venture agreement (see “JV” below), pediatric melanoma for CAP4 and acute myeloid leukemia (“AML”) for Oxi4503. In addition, the Company, through it’s JV, is developing 5 additional products for treatments of various cancers. Each of the products being developed by the JV has the potential of becoming very successful drugs. The JV is contemplating developing and obtaining regulatory approval for each of the 5 additional products via different regulatory pathways and in various countries and regions. Further, the Company aims to capitalize on a voucher program in the United States (“US”). By focusing on capitalizing on the RPD we anticipate: 1) reducing the cost of clinical development by way of a smaller and faster clinical trial, 2) acceleration of the approval process and final approval, 3) obtaining regulatory/ marketing exclusivity for up to 1
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 1.01Item 1.01 - Entry into Material Agreement
Item Entry
1.01 into a Material Definitive Agreement.
On
June 23, 2026, Oncotelic Therapeutics, Inc. (the “Company” or “Our”) entered into a Securities Purchase Agreement
(the “2026 Pacific Pier SPA ”), with Pacific Pier Capital II, LP (“ Pacific Pier ”), and the Company
issued a convertible promissory note in the aggregate gross principal amount of $178,410 (the “ 2026 Pacific Pier Note ”).
The 2026 Pacific Pier Note is convertible into shares of the Company’s common stock, par value $0.01 per share (“ Common
Stock ”).
The
2026 Pacific Pier Note has an original issue discount of 12%, carries an interest rate of 12% per annum and matures on the earlier of
(a) the one-year anniversary of the date of the 2026 Pacific Pier SPA, or (b) the acceleration of the maturity of the 2026 Pacific Pier
Note by Pacific Pier upon occurrence of an Event of Default (as defined below) or (c) on prepayment in full. The 2026 Pacific Pier Note
contains a voluntary conversion mechanism whereby Pacific Pier may convert the outstanding principal and accrued interest under the terms
of the 2026 Pacific Pier Note into shares of Common Stock (the “ Conversion Shares ”), at a fixed price of $0.06 per
share (the “ Conversion Price” ) or 85% of the lowest traded price of the Common Stock on the Principal Market on any
Trading Day during the ten (10) Trading Days prior to the respective Conversion Date, subject to adjustments upon the occurrence of certain
corporate events. The Company also issued 500,000 shares of Common Stock of the Company as commitment shares (“ Commitment
Shares ”) to Pacific Pier. Prepayment of the 2026 Pacific Pier Note may be made at any time upon three trading days’
after six months of the date of the 2026 Pacific Pier Note, with prior written notice to the respective holder, by payment of the then
outstanding principal amount plus accrued and unpaid interest and reimbursement of such holder’s administrative fees. The 2026
Pacific Pier Note contains customary events of default (each an “ Event of Default ”). If an Event of Default occurs,
at the respective holder’s election, the outstanding principal amount of the 2026 Pacific Pier Note, plus accrued but unpaid interest,
will become immediately due and payable in cash and at a default interest at 16%.
The
issuance of the 2026 Pacific Pier Note and the Commitment Shares are exempt from the registration requirements of the Securities
Act of 1933, as amended (“ Securities Act ”), in reliance on the exemptions provided by Section 4(a)(2) of the Securities
Act. The shares of Common Stock issuable upon conversion of the 2026 Pacific Pier Note and the Commitment Shares have not been
registered under the Securities Act or any other applicable securities laws, and unless so registered, may not be offered or sold in
the United States except pursuant to an exemption from the registration requirements of the Securities Act.
The
foregoing descriptions of the 2026 Pacific Pier Purchase Agreement, the 2026 Pacific Pier Note and Pacific Pier Registration Rights Agreement
are qualified in their entirety by reference to the full text of the form of such agreements, copies of which are attached as Exhibit
10.1 and 10.2, respectively, and each of which is incorporated herein in its entirety by reference.
-2-
Item 2.03Item 2.03 - Creation of Direct Financial Obligation
Item Creation
2.03 of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
See
Item 1.01, above.
Item 3.02Item 3.02 - Unregistered Sales of Equity
Item Unregistered
3.02 Sale of Equity Securities.
See
Item 1.01, above.